Multiparameter Prediction Model of Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer: a Real-world Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Progression-free survival（PFS）in days
研究概览
简要总结
The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors will achieve durable clinical benefit for chemo-immunotherapy are needed. This study is a real world study, aiming to establish a multi-parameter model to predict the efficacy of immune checkpoint inhibitor(ICI) combined with chemotherapy, and to explore the correlation and predictive value of each single biomarker, so as to assist physician to select patients who may benefit for a long time as early as possible and guide clinical accurate treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female, ≥18 years old;
- •Patients with a definite cytological or histopathological diagnosis of non-small cell lung cancer;
- •Locally advanced (stage IIIB/IIIC) or metastatic (stage IV) NSCLC unable to receive radical surgery and/or radical radiotherapy (with or without concurrent chemotherapy) (AJCC cancer stage 8 clinical stage)
- •There is no known ALK gene translocation
- •For patients with EGFR-negative non-squamous cell carcinoma, or patients with EGFR-negative/unknown squamous cell carcinoma, it is required that they have not received systemic antitumor therapy for advanced NSCLC in the past (patients have received neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy or chemoradiotherapy for curing non-metastatic disease in the past, A disease-free interval of ≥6 months was required between the last chemotherapy and/or radiotherapy).
- •Patients with non-squamous cell carcinoma with EGFR-sensitive mutation and EGFR TKI progression could be enrolled if they met any of the following requirements:
- •Progress in Treatment of 1/2 generation EGFR TKI, T790M-; EGFR TKI treatment progress of 1/2 generation, T790M+, after 3 generations of EGFR TKI treatment progress again; T790M status was not considered in patients who had progressed to the initial 3 generations of EGFR TKI therapy.
- •At least 1 measurable lesion according to RECIST 1.1
- •Receiving immune checkpoint inhibitor therapy for more than 2 cycles
- •ECOG PS 0-1 score
- •Be able to understand and abide by the requirements of the agreement, and voluntarily participate in the study.
排除标准
- •Patients participating in other clinical studies;
- •Patients with serious lack of diagnosis and treatment data;
- •Patients could not understand the purpose of the study or disagreed with the requirements of the study;
- •A history of other tumors within 5 years;
- •Patients judged by the researchers as not suitable for inclusion in this study
结局指标
主要结局
Progression-free survival（PFS）in days
时间窗: From date of enrollment until the date of first documented progression, assessed up to 2 years.
the time between the time a patient with tumor disease begins treatment and the time when disease progression is observed or death from any cause occurs.
次要结局
- ctDNA in concentration(The First treatment (month 1), the second treatment (month 2) and the time of progression (assessed up to 2 years))